Understand ovarian cancer treatment options: A clinical overview of current care pathways

Understanding ovarian cancer treatment options requires looking at how clinicians combine local treatment, such as surgery, with medicines that act throughout the body. The appropriate plan depends on the cancer’s size and type, location, spread, general health, genetic findings and whether the disease is newly diagnosed or recurrent. 1

How treatment plans are determined

Specialist teams assess the stage and grade of the cancer, the amount of disease in the body, the presence of abdominal fluid, whether visible tumors can be removed, and the person’s age, health and fitness. Genetic information, including BRCA1 and BRCA2 results, can also influence treatment choices. Gynecologic oncologists, medical oncologists and radiation specialists may contribute to the plan. 2

The type of tumor matters because epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, germ-cell tumors and sex-cord stromal tumors can have different treatment patterns. High-grade epithelial cancers commonly require molecular testing, while some hormone-responsive tumors may be considered for hormone treatment. The patient’s wishes, including fertility considerations, are also part of decision-making. 3

Surgery and tumor reduction

Surgery is a central treatment for many patients. Early-stage operations may remove one or both ovaries and fallopian tubes, and may also include removal of the uterus and cervix through an abdominal hysterectomy. When cancer has spread, surgeons may remove as much visible disease as possible, including fatty abdominal tissue, lymph nodes and, in some cases, portions of the bowel or other organs. 1

Common surgical components can include a total hysterectomy, bilateral salpingo-oophorectomy, omentectomy and lymph-node sampling, although the exact operation varies by disease extent and individual circumstances. The objective is to reduce tumor burden while considering operative risks, recovery and future fertility. Cancer centers with gynecologic oncology expertise may be involved when extensive abdominal surgery is being considered. 6

Chemotherapy before or after surgery

Chemotherapy uses medicines that kill cancer cells and may be given before surgery, after surgery or without surgery in selected circumstances. For advanced epithelial ovarian cancer, the reported standard first-line approach is six cycles of paclitaxel and carboplatin given every three weeks. Lower-dose weekly schedules may be considered for frail patients, showing how fitness can affect the regimen. 3

Platinum-based chemotherapy may also be used when ovarian cancer returns. A preoperative, or neoadjuvant, approach can shrink tumors before an operation when immediate complete removal appears difficult. Combination chemotherapy uses more than one anticancer medicine, but treatment can involve substantial side effects, so specialists discuss expected benefits, toxicity and monitoring as part of the treatment plan. 2

Targeted and maintenance therapies

Targeted medicines are selected according to tumor biology and treatment history rather than used uniformly for every patient. PARP inhibitors, including olaparib, niraparib and rucaparib, have become important maintenance treatments for selected patients, particularly when BRCA1 or BRCA2 mutations or homologous recombination deficiency are identified. Testing may therefore affect eligibility for maintenance therapy after an initial response. 7

Antiangiogenic treatment is another targeted strategy. Bevacizumab inhibits blood-vessel growth that can support tumors and may be combined with chemotherapy or continued as maintenance in appropriate cases. Newer treatment development includes antibody-drug conjugates such as mirvetuximab soravtansine, while regulatory approvals and guideline updates continue to change options for advanced or recurrent disease. 7

Other treatment approaches

Intraperitoneal chemotherapy delivers heated or non-heated medicine into the abdominal cavity, where ovarian cancer frequently spreads. Hyperthermic intraperitoneal chemotherapy, known as HIPEC, uses heated chemotherapy circulated through the abdomen during a specialized treatment approach. It is not suitable for everyone and depends on disease distribution, surgical findings, health status and the expertise available at the treating center. 2

Radiotherapy is generally not the main treatment for ovarian cancer, but it may be used for symptom relief in recurrent or advanced disease. Hormone therapy may be considered for selected low-grade serous or sex-cord stromal tumors that respond to hormonal signals. Immunotherapy and other immune-based treatments remain areas of clinical development, with activity varying by tumor biology and treatment setting. 8

Recurrence, trials and continuing care

Ovarian cancer can recur after an initial response, making treatment after relapse dependent on the timing of recurrence, prior medicines, tumor genetics, symptoms and overall health. Options may include additional chemotherapy, targeted medicines, surgery in selected cases, radiotherapy for localized symptoms or a clinical trial. Research is examining antibody-drug conjugates, bispecific antibodies, radioligand treatments, cellular therapies and vaccines. 8

Clinical trials can provide access to emerging therapies or combinations, but eligibility criteria may include tumor type, prior treatments, laboratory results and general health. Treatment also involves surveillance: the NHS reports that patients have regular check-ups during and after treatment and may undergo tests and scans. New or troublesome symptoms and side effects should be reported to the specialist team rather than postponed until the next scheduled review. 1

Questions that clarify treatment choices

Useful discussions with a treatment team cover the cancer’s exact histologic type, stage and grade; whether surgery is recommended first; whether chemotherapy is planned before or after surgery; and whether all visible disease can reasonably be removed. Questions about BRCA1, BRCA2 and other tumor testing can clarify whether maintenance or biomarker-directed treatment is relevant. Fertility, menopause, recovery and quality-of-life priorities should also be addressed. 2

Risks and practical limitations differ across approaches. Extensive surgery may involve several abdominal organs, chemotherapy can cause significant side effects, and targeted treatments may require biomarker evidence or meet regulatory criteria. Treatment recommendations can change as evidence and approvals develop, particularly for recurrent disease. A written plan should identify the intended goal, monitoring schedule, warning symptoms and what happens if the cancer responds, remains stable or returns. 3

Sources

1. NHS, Ovarian cancer: Treatment
2. Penn Medicine, Ovarian Cancer Treatment
3. Medscape, Epithelial Ovarian Cancer: ESMO 2026 Guideline Summary
4. ColumbiaDoctors, Ovarian Cancer: Symptoms and Treatment
5. Cancer Council NSW, Ovarian cancer treatment
6. Fred Hutch Cancer Center, Treatments and Therapies for Ovarian Cancer
7. Journal of Ovarian Research, From cytoreduction to precision oncology: evolution of ovarian cancer therapy
8. Cold Spring Harbor Perspectives in Medicine, Ovarian Cancer Therapy